StockData
Faeth Therapeutics, Inc. logo

Faeth Therapeutics, Inc. (FTH) stock

FTHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30
$9.04−0.24 (-2.59%)

Close on Nov 17, 2026Market cap $233.60MP/E –Yield –

Faeth Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Faeth Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$198.82M. For fiscal 2025 it was -$22.29M. The highest annual figure on record is -$19.45M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$22.29M–
FY2024Dec 31, 2024-$32.61M–
FY2023Dec 31, 2023-$37.06M–
FY2022Dec 31, 2022-$50.19M–
FY2021Dec 31, 2021-$37.48M–
FY2020Dec 31, 2020-$19.45M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$18.39M–
Q1 FY2026Mar 31, 2026-$170.63M–
Q4 FY2025Dec 31, 2025-$4.96M–
Q3 FY2025Sep 30, 2025-$4.85M–
Q2 FY2025Jun 30, 2025-$5.21M–
Q1 FY2025Mar 31, 2025-$7.27M–
Q4 FY2024Dec 31, 2024-$8.27M–
Q3 FY2024Sep 30, 2024-$7.82M–
Q2 FY2024Jun 30, 2024-$7.79M–
Q1 FY2024Mar 31, 2024-$8.73M–
Q4 FY2023Dec 31, 2023-$8.14M–
Q3 FY2023Sep 30, 2023-$7.74M–
Q2 FY2023Jun 30, 2023-$10.18M–
Q1 FY2023Mar 31, 2023-$11.01M–
Q4 FY2022Dec 31, 2022-$13.05M–
Q3 FY2022Sep 30, 2022-$13.94M–
Q2 FY2022Jun 30, 2022-$10.71M–
Q1 FY2022Mar 31, 2022-$12.49M–
Q4 FY2021Dec 31, 2021-$9.41M–
Q3 FY2021Sep 30, 2021-$10.32M–
Q2 FY2021Jun 30, 2021-$9.78M–
Q1 FY2021Mar 31, 2021-$7.97M–
Q4 FY2020Dec 31, 2020-$5.08M–
Q3 FY2020Sep 30, 2020-$5.36M–
Q2 FY2020Jun 30, 2020-$4.91M–
Q1 FY2020Mar 31, 2020-$4.10M–

More Faeth Therapeutics figures

See a number that looks wrong?